User profiles for Deborah L. White
 | Deborah WhiteProfessor. Director Precision Cancer Medicine Theme SAHMRI Verified email at sahmri.com Cited by 9232 |
[HTML][HTML] Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia
…, JA Whitlock, EA Raetz, DL White… - New England journal …, 2014 - Mass Medical Soc
Background Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL) is
characterized by a gene-expression profile similar to that of BCR–ABL1–positive ALL, …
characterized by a gene-expression profile similar to that of BCR–ABL1–positive ALL, …
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
…, RJ Filshie, AK Mills, JV Melo, DL White… - Blood, The Journal …, 2013 - ashpublications.org
Most patients with chronic myeloid leukemia (CML) treated with imatinib will relapse if
treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 …
treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 …
OCT-1–mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro …
DL White, VA Saunders, P Dang, J Engler… - Blood, 2006 - ashpublications.org
Intrinsic sensitivity of newly diagnosed chronic myeloid leukemia (CML) patients to imatinib (IC50
imatinib ) correlates with molecular response. IC50 imatinib is defined as the in vitro …
imatinib ) correlates with molecular response. IC50 imatinib is defined as the in vitro …
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 …
DL White, VA Saunders, P Dang… - Blood, The Journal …, 2007 - ashpublications.org
Interpatient variability in intracellular uptake and retention (IUR) of imatinib may be due to
variable function of the OCT-1 influx pump. OCT-1 activity was measured in pretherapy blood …
variable function of the OCT-1 influx pump. OCT-1 activity was measured in pretherapy blood …
Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications
Purpose: The organic cation transporter OCT-1 mediates active transport of imatinib. We
recently showed that low OCT-1 activity is a major contributor to suboptimal response in chronic …
recently showed that low OCT-1 activity is a major contributor to suboptimal response in chronic …
[PDF][PDF] Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib
DL White, P Dang, J Engler, A Frede, S Zrim… - J Clin Oncol, 2010 - academia.edu
Purpose Organic cation transporter-1 (OCT-1) activity (OA), a measure of the OCT-1–mediated
influx of imatinib into CML mononuclear cells (MNCs), is predictive of major molecular …
influx of imatinib into CML mononuclear cells (MNCs), is predictive of major molecular …
CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors
…, J Clarson, C Tang, L Vidovic, DL White… - Blood, The Journal …, 2017 - ashpublications.org
Immunological control may contribute to achievement of deep molecular response in
chronic myeloid leukemia (CML) patients on tyrosine kinase inhibitor (TKI) therapy and may …
chronic myeloid leukemia (CML) patients on tyrosine kinase inhibitor (TKI) therapy and may …
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease
…, SY Choi, SH Park, DW Kim, DL White… - Blood, The Journal …, 2018 - ashpublications.org
Genomic events associated with poor outcome in chronic myeloid leukemia (CML) are poorly
understood. We performed whole-exome sequencing, copy-number variation, and/or RNA …
understood. We performed whole-exome sequencing, copy-number variation, and/or RNA …
Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy
We conducted a trial in 103 patients with newly diagnosed chronic phase chronic myeloid
leukemia (CP-CML) using imatinib 600 mg/day, with dose escalation to 800 mg/day for …
leukemia (CP-CML) using imatinib 600 mg/day, with dose escalation to 800 mg/day for …
[HTML][HTML] Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia
Successful treatment of acute myeloid leukemia (AML) with chimeric antigen receptor (CAR)
T cells is hampered by toxicity on normal hematopoietic progenitor cells and low CAR T cell …
T cells is hampered by toxicity on normal hematopoietic progenitor cells and low CAR T cell …